Stress ulcer, gastritis, and gastrointestinal bleeding prophylaxis in critically ill pediatric patients: A systematic review

Size: px
Start display at page:

Download "Stress ulcer, gastritis, and gastrointestinal bleeding prophylaxis in critically ill pediatric patients: A systematic review"

Transcription

1 Review Articles Stress ulcer, gastritis, and gastrointestinal bleeding prophylaxis in critically ill pediatric patients: A systematic review Ludovic Reveiz, MD, MSc; Rafael Guerrero-Lozano, MD; Angela Camacho, MD; Lina Yara, MD; Paola Andrea Mosquera, Psi, MSc Objective: To identify and evaluate the quality of evidence supporting prophylactic use of treatments for stress ulcers and upper gastrointestinal bleeding. Stress ulcers, erosions of the stomach and duodenum, and upper gastrointestinal bleeding are well-known complications of critical illness in children admitted to the pediatric intensive care unit. Data Sources: Studies were identified from the Cochrane Central Register of Controlled Trials, PUBMED; LILACS; Scirus. We also scanned bibliographies of relevant studies. Study Selection: This systematic review of randomized controlled trials assessed the effects of drugs for stress-related ulcers, gastritis, and upper gastrointestinal bleeding in critically ill children admitted to the pediatric intensive care unit. Data Extraction and Synthesis: Two reviewers independently extracted the relevant data. Most randomized s were judged as having unclear risk of bias. When pooling two randomized s, treatment was significantly more effective in preventing upper gastrointestinal bleeding (macroscopic or important bleeding) compared with no treatment (two studies 300 participants; relative risk, 0.41; 95% confidence interval, ; I 2 12%). Meta-analysis of two studies found no significant difference in death rates among groups (two randomized s 132 participants; relative risk, 1.39; 95% confidence interval, ; I 2 4%). The rate of pneumonia was not significantly different when comparing treatment and no treatment in one study. When comparing ranitidine with no treatment, significant differences were found in the proportion of mechanically ventilated children with normal gastric mucosal endoscopic findings by histologic specimens (one randomized 48 participants; relative risk, 3.53; 95% confidence interval, ). No significant differences were found when comparing different drugs (omeprazole, ranitidine, sucralfate, famotidine, amalgate), doses, or regimens for main outcomes (deaths, endoscopic findings of erosion or ulcers, upper gastrointestinal bleeding, or pneumonia). Conclusions: Although pooled data of two studies suggested that critically ill pediatric patients may benefit from receiving prophylactic treatment to prevent upper gastrointestinal bleeding, we found that high-quality evidence to guide clinical practice is still limited. (Pediatr Crit Care Med 2010; 11: ) KEY WORDS: children; stress ulcer; gastrointestinal bleeding; intensive care unit; critical care; prophylaxis; systematic review Stress ulcers of the stomach and duodenum as well as upper gastrointestinal (UGI) bleeding are well-known complications of critical illness in children admitted to a pediatric intensive care unit (ICU). The prevalence of stress ulceration in critically ill adults and children may vary depending on the severity of the illness and methods used for diagnosis. A cohort of 1006 consecutive admissions enrolled in a pediatric ICU reported that 10.2% of pediatric participants had UGI bleeding From the Research Institute (LR, PAM), Grupo de Evaluación de Tecnologías, and the Department of Pediatrics (RG-L, AC, LY), National University of Colombia, Bogotá, Colombia. The authors have not disclosed any potential conflicts of interest. For information regarding this article, mmreveiz@hotmail.com Copyright 2010 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies DOI: /PCC.0b013e3181b80e70 and 1.6% had clinically significant UGI bleeding (1). Clinically important UGI bleeding has an important attributable morbidity and mortality in adults, associated with a significant risk of death (relative risk [RR], 4.1; 95% confidence interval [CI], ) and an excess length of ICU stay of approximately 4 to 8 days (2). Clinically important UGI bleeding is defined as macroscopic bleeding that results in hemodynamic instability and the need for red blood cell transfusion and may lead to complications, such as gastrointestinal perforations and surgery (3, 4). Prophylaxis against stress ulcers has been recommended for the prevention of UGI bleeding in critically ill adults patients. A systematic review published more than one decade ago found that prophylaxis with histamine2-receptor antagonists decreases the occurrence of overt gastrointestinal bleeding (odds ratio [OR], 0.58; 95% CI, ) and clinically important bleeding (OR, 0.44; 95% CI, ) (5). Another study found that, among critically ill adult patients requiring mechanical ventilation, those receiving ranitidine had a significantly lower rate of clinically important gastrointestinal bleeding than those treated with sucralfate and no significant differences were found in the rates of ventilator-associated pneumonia, the duration of the stay in the ICU, or mortality (6). However, a more recent integrative study found that ranitidine was ineffective in the prevention of UGI bleeding in patients in intensive care compared with placebo (OR, 0.72; 95% CI, ) and might increase the risk of pneumonia when compared with sucralfate (OR, 1.35; 95% CI, ) and that studies on sucralfate do not provide conclusive positive results (7). A guideline on stress ulcer prophylaxis published in 2006 recommended pharmacologic intervention in adults admitted to the ICU who have coagulopathy, require mechanical ventilation for 48 hrs, have a his- 124 Pediatr Crit Care Med 2010 Vol. 11, No. 1

2 tory of gastrointestinal ulceration or bleeding within 1 yr before admission, or have at least two of the following risk factors: sepsis, ICU stay of 1 wk, occult bleeding lasting 6 days, and use of 250 mg of hydrocortisone or the equivalent (8). Unfortunately, there is still conflicting evidence concerning prophylaxis for stress ulcers in children and we did not find any systematic review on this topic. The aims of the systematic review presented here are to assess the best evidence on the effects of interventions for stress ulcer in children, to identify gaps in the literature, and to suggest further clinical investigation. METHODS Literature Search Relevant randomized s (RCTs) were identified from the Cochrane Central Register of Controlled Trials (The Cochrane Library 2008, Issue 3), PubMed (1966 to June 2008), LILACS (1982 to June 2008), and Scirus (June 2008). A search strategy to locate studies on stress ulcer, UGI in children was structured and adapted according to each electronic database (Appendix A). The International Clinical Trials Registry Platform search portal ( the metaregister of s ( and clinicaltrials.gov/ were searched for ongoing trials. Eligible RCTs were included regardless of the language of publication. We also scanned bibliographies of relevant studies for possible references to additional RCTs. Study Selection Two authors independently decided which trials fit the inclusion criteria. Any disagreements were resolved by discussion between the reviewers, with referral to a third author if necessary. Only RCTs of interventions for stress ulcer in hospitalized children (studies that included participants aged 18 yrs) were considered in this systematic review. We considered any hospitalized children including critically ill pediatric patients having or not having mechanical ventilation, children admitted to pediatric ICUs or who underwent surgery, preterm and full-term newborns among others. Quasirandomized and nonrandomized controlled studies were not discussed further. We considered all doses and regimen treatments as single or combined therapy used as prophylaxis against stress ulcers. The comparators were placebo, no treatment, or another active compound. Data Extraction At least two reviewers (L.R., L.Y., P.A.M.) independently extracted the relevant data, using a predesigned data extraction form; disagreement was resolved by consensus with all authors. We extracted year of publication, patient population, number of patients (by intention to treat), aspects of study quality, sociodemographic, interventions (drug, dose, duration of treatment), clinical, endoscopic, and histologic outcomes and adverse effects. Risk of Bias Assessment/GRADE System The Cochrane Collaboration recently proposed a new tool having six domains to assess the risk of bias of RCTs (namely, sequence generation of randomization, allocation concealment to prevent foreknowledge of group assignment in an RCT, blinding, incomplete outcome data, selective outcome reporting and other issues ). Therefore, a risk of bias evaluation of each RCT was done for the assessment of these features (9). Additional quality information reported included also information of withdrawals, inclusion and exclusion criteria, sample size calculation, and baseline comparability of age, gender, relevant clinical characteristics and diagnoses and duration of complaint. The tool for assessing risk of bias in each RCT comprises a description and a judgment for each entry in a risk of bias table. The judgment for each entry involves answering a question, with answers Yes indicating low risk of bias, No indicating high risk of bias, and Unclear indicating either lack of information or uncertainty over the potential for bias. A study should be considered as having low risk of bias if all key domains were judged as Yes and with unclear risk if the reviewers judged Unclear risk of bias for one or more key domains (9). We also used the GRADE system for grading the quality of evidence and the strength of recommendations by two reviewers. A systematic approach for grading the strength of management recommendations can minimize bias and aid interpretation of clinical practice guidelines. This system takes into account study design, study quality, consistency, and directness in judging the quality of evidence for each important outcome (10). Definitions and Outcomes The main outcomes considered were death; presence of ulcers, gastritis, or UGI bleeding; bleeding that requires transfusion; bleeding associated with hemodynamic instability; gastrointestinal perforations; and pneumonia. In addition, endoscopic findings categorized according to the severity of UGI tract lesions were also considered primary outcome. We anticipated that diverse classifications could have been used by trialists. Other outcomes were: delayed gastric emptying; bacteremia during the follow-up; mean patient s gastric aspirates ph during 24-hr monitoring, pediatric ICU stay; duration of mechanical ventilation hematologic test; cultures of gastric and tracheal secretion, gastric and tracheal colonization; and complicated postoperative course. We only included data on adverse events from RCTs; no further searches for other types of studies were done (11). Statistical Analysis Statistical analyses were done with Review Manager version 5.0 (Cochrane Collaboration) software. The results expressed as RR and 95% CI for dichotomous primary outcomes were calculated by the Mantel-Haenszel fixedeffects model. Weighted mean difference with 95% CI was used for continuous outcomes. For the pooled analysis, we calculated the I 2 statistic, which describes the percentage of total variation across studies caused by heterogeneity (9). Low, moderate, and high levels of heterogeneity approximately correspond to I 2 values of 25%, 50%, and 75%, respectively. RESULTS Description of Studies A total of 294 citations were identified from the diverse sources of information. Of the 74 potentially RCTs screened, we excluded 52 references because they were guidelines, observational studies, or case series reports. We identified 22 studies assessing the effects of different therapeutic interventions for stress ulcers in children (Fig. 1). However, we excluded 13 studies because they were nonrandomized or noncontrolled or focused on pharmacokinetics of drugs (12 24). One study in Hungarian is pending for evaluation (25). In total, we included and analyzed eight RCTs evaluating the effects of drugs for preventing stress ulcers in children (26 33). The main characteristics of the eight included studies are detailed in Table 1. Table 1: We could not assess publication bias (e.g., funnel plot or Egger regression test) because we found less than nine RCTs and we could not pool outcomes for more than three studies. Risk of Bias Seven studies were open and we found no RCT with low risk of bias. Overall six Pediatr Crit Care Med 2010 Vol. 11, No

3 Figure 1. Flow diagram of the process of identifying and including references. treated in a neonatal ICU showed that rates of normal gastric mucosal endoscopic findings by visual inspection (one RCT 48 participants; RR, 3.04; 95% CI, ) and histologic specimens (one RCT 48 participants; RR, 3.53; 95% CI, ) were significantly higher in the ranitidine group compared with no treatment groups. However, no significant differences among groups were found in the rates of patients with erosions or ulceration, gastrointestinal problems (bleeding from the gastrointestinal tract and/or vomiting or delayed gastric emptying), positive bacterial cultures from the biopsy specimens, and the risk for later suspected or proven bacteremia during the follow-up. An RCT of children who needed mechanical ventilation on admission (30) showed no significant difference between groups in macroscopic bleeding, pneumonia occurrence, duration of mechanical ventilation (days) and pediatric ICU stay (days). Another RCT of children admitted to a pediatric ICU (28) did not show statistical difference in the rates of patients with important UGI hemorrhage among groups. A significant difference favoring ranitidine was found in the percentage of children with mean ph of 4 during 50% of study time compared with no treatment (one RCT 70 participants; RR, 8.67; 95% CI, ). RCTs were judged as having unclear risk of bias mainly because the description of the method used to generate the sequence of randomization and to conceal the allocation was unclear (Table 2). Some markers of quality in medical research, such as performing a sample size calculation, are unlikely to have direct implications for risk of bias. However, the majority of RCTs did not calculate the sample size, which is a source of potential imprecision. Overall the quality of the reporting and design of the RCTs was poor. Effects of Interventions Treatment Versus No Treatment We found four studies that evaluated a number of medications (cimetidine, almagate, ranitidine, sucralfate, and omeprazole) vs. no treatment or placebo for different outcomes; data were not available in all RCTs for each outcome (26, 28, 30, 33). When pooling two RCTs (Fig. 2), treatment (which included almagate, ranitidine, sucralfate, and omeprazole) was significantly more effective in preventing UGI bleeding (macroscopic or important bleeding) compared with no treatment (two studies 300 participants; RR, 0.41; 95% CI, ; I 2 12%) (28, 30). However, no significant difference was found when pooling both studies of treatment vs. no treatment with an additional RCT comparing treatment vs. placebo (three studies 340 participants; RR, 0.69; 95% CI, ; I 2 63%) (26, 28, 30). In addition, metaanalysis of two studies (30, 33) found no significant difference in death rates among groups (two RCTs 132 participants; RR, 1.39; 95% CI, ; I 2 4%). The rate of pneumonia was not significantly different when comparing treatment and no treatment in one study (30). Summary of relevant findings for primary outcomes of RCTs included in the review are detailed in Table 3. Ranitidine One RCT (33) in mechanically ventilated preterm and full-term newborns Amalgate An RCT (28) showed a significant difference favoring amalgate in the percentage of patients gastric aspirates with mean ph of 4 during 50% of study time (one RCT 70 participants; RR, 11.00; 95% CI, ). No significant difference was found among groups regarding the rates of patients with important UGI hemorrhage. Sucralfate In one RCT (28), a trend favoring sucralfate was found in the percentage of patients gastric aspirates with mean ph of 4 during 50% of study time (one RCT 70 participants; RR, 3.33; 95% CI, ). However, no significant difference between groups was found for other outcomes, such as rate of patients with important UGI hemorrhage. Another RCT (30) did not report significant difference among groups in rates of macroscopic bleeding, pneumonia, and deaths as well as in the duration of me- 126 Pediatr Crit Care Med 2010 Vol. 11, No. 1

4 Table 1. Characteristics of randomized s included in the review Study Methods Participants Interventions Outcomes Aanpreung et al (31) Behrens et al (32) Kuusela et al (33) Lacroix et al (26) patients from the pirenzepine or famotidine group were randomized. No treatment group vs. treatment group was not randomized. Double-blind randomized Lopez-Herce et al (27) Lopez-Herce et al (28) Twenty critically ill pediatric patients aged 2 mos to 12 yrs. Severity of disease was assessed using Zinner index score. Children who underwent corrective or palliative surgery for congenital heart disease. Age, weight, cardiopulmonary bypass time, aortic cross clamp period, and mean interval between endoscopy and cardiac surgery were not significantly different in the two groups. The study group was prospectively collected from mechanically ventilated preterm and full-term newborns treated in a neonatal ICU. The criterion for inclusion in the study was the start of mechanical ventilation during the first 2 hrs of life. Most of the infants were preterm; the mean gestational age was 32 wks (range wks) and the mean birth weight was 1832 g (range g). Twenty-nine of the neonates were male and 24 were female. Altogether, 37 preterm infants of gestational age of 33 wks and 16 infants of gestational age of 33 wks were enrolled in the study. Forty children from birth to 18 yrs old admitted to PICU. Inclusion criteria were that illness was severe enough to preclude any oral or enteral nutrition for at least 2 days. Exclusion criteria: UGI bleeding, burns, or surgical problems; need of oral or enteral feeding; renal failure or cerebral death; treatment requiring cimeridine or antiacids. Mean SD age was yrs. Forty patients admitted to PICU ranging from neonate to 17 yrs old were included. 165 children admitted to PICU presenting at least one of the following criteria: shock, acute renal, cardiac respiratory or liver failure, sepsis or serious focal infection, coagulopathy, acute neurologic dysfunction, multiple trauma, severe metabolic acidosis post major surgery. All patients had nasogastric tube inserted. Severity of illness was evaluated with three scores. Intravenous ranitidine 1.5 mg/kg every 6 hrs and famotidine 0.4 mg/kg every 8 hrs The first 36 patients (group 1) were not given treatment to prevent lesions of the UGI tract. Later, 43 patients (group 2) were randomized and treated either with pirenzepine, an anticholinergic (21 patients) or famotidine, a H2 antagonist (22 patients). Both drugs were given intravenously at a dosage of 1 mg/ kg/day. In older patients, the drugs were given as two doses; children who weighed 10 kg were given three doses. Fifty-three mechanically ventilated newborns were randomized into either the treatment group (prophylactic intravenous ranitidine 5 mg/kg body weight/day divided into three doses throughout 4 days) or the control group (no prophylaxis). Prophylactic treatment commenced immediately parallel to mechanical ventilation. There was no placebo treatment available. Patients were randomized to cimetidine 0.13 ml/kg/day (ampoule 150/mg/mL) or placebo every 6 hrs as long as 10 days. Patients were randomized into four groups. All of them received ranitidine at different dosages: a) 2 mg/kg by nasogastric tube every 12 hrs; b) 4 mg/kg by nasogastric tube every 12 hrs; c) 0.75 mg/kg iv every 6 hrs; d) 1.5 mg/kg iv every 6 hrs. Participants were randomized to four groups: no treatment; almagate 0.25 ml/kg every 2 hrs; ranitidine 1.5 mg/kg iv every 6 hrs; and sucralfate 0.5 gr if weighing 10 kg and 1 gr if weighing 10 kg every 6 hrs. Patients intragastric ph was measured by continuous ph monitoring digitrapper. Intensity of UGI hemorrhage was classified into three categories: nonhemorrhage; slight; and important. All patients had at least one endoscopic examination performed by the same examiner as the patients still required mechanical ventilation. To assess the severity of lesions of the UGI tract, authors developed a score based on the endoscopic findings: Normal findings 0; Mild-to-moderate inflammation, few petechiae or erosions 1; Pronounced inflammation, multiple petechiae erosions 2; Ulcer(s) 3. Additional outcomes: continuous 24-hr measurement of ph; tracheal and gastric secretions culture; daily routine chest radiographs on the first 3 postoperative days and afterwards chest radiographs were taken if indicated by the clinical findings. The primary outcome variable was mucosal lesions detected endoscopically. The procedure was planned for all patients at the age of 3 to 6 days. The findings were grouped into four categories: a) intact gastric mucosa; b) mucosal friability; c) erythema or gross blood; and d) erosions or ulcers. Gastric mucosal biopsy specimens were obtained for histological and bacteriologic evaluation if there were no contraindications. Alcian-blueperiodic-acid-Schiff and modified Giemsa stains were used to demonstrate fungi and bacteria. Biopsy specimens were also obtained for bacterial culture. UGI bleeding noted from nasogastric tube. Massive UGI bleeding was defined as brown hemorrhage from nasogastric tube and a decrease in arterial blood pressure of 20 mm Hg or with an acute decrease of hemoglobin of 2 mg/ dl ph measurements. Treatment was considered successful when gastric ph was 4 during 80% of the study time on each patient. Gastric ph evolution, UGI hemorrhage occurrence rate, microscopic upper gastrointestinal hemorrhage, mortality, adverse events. Pediatr Crit Care Med 2010 Vol. 11, No

5 Table 1. Continued Study Methods Participants Interventions Outcomes Osteyee et al (29) cross over trial Sixteen critically ill children. 160 patients who needed mechanical ventilation on admission were enrolled in the study. Patients were excluded if any of the following circumstances occurred in the first 48 hrs after inclusion: extubation, death, pneumonia, or new information that the patient had received one of the study drugs in the last 48 hrs before admission. Children in group 1 received bolus dosing on day 1 and continuous infusion of ranitidine on day 2. Group 2 received the continuous infusion on day 1 and bolus dosing on day 2. Continuous infusion regimen: ranitidine bolus of 0.15 mg/kg followed by continuous infusion at 0.15 mg/kg per hour for 12 hrs. Bolus regimen: 1 mg/kg, two doses 6 hrs apart. Group S received sucralfate suspension 60 mg/kg/day in four doses via the nasogastric tube that was flushed with 10 ml of sterile water; group R received ranitidine 2 mg/kg/day intravenously in four doses; group O received omeprazole 1 mg/kg/day intravenously in two doses; and group P did not receive any medication for stress ulcer prophylaxis. Gastric ph. Ventilator-associated pneumonia was defined as the occurrence of a new or persistent radiographic infiltrate in conjunction with one of the following: positive pleural/blood culture with the same organism recovered in the tracheal aspirate or sputum, radiographic cavitation, histopathologic evidence of pneumonia; or at least two of the following: fever; leukocytosis; and purulent tracheal aspirate or sputum. Pneumonia was considered to be ventilator associated if it occurred after a minimum of 48 hrs after the initiation of mechanical ventilation. Respiratory tract culture specimens were obtained from tracheal aspirates. Hospital mortality was defined as patient death occurring in the PICU and hospital stay was defined as the days in the PICU. UGI, upper gastrointestinal; H2 antagonists, histamine H2-receptor antagonists; ICU, intensive care unit; PICU, pediatric intensive care unit; SD, standard deviation. chanical ventilation and pediatric ICU stay. Omeprazole In one RCT (28), omeprazole was not superior to no treatment in groups in rates of macroscopic bleeding, pneumonia, deaths, and in the duration of mechanical ventilation and pediatric ICU stay. Cimetidine In one RCT (26), cimetidine was not superior to placebo in rates of UGI bleeding. Drug Vs. Any Other Active Compound We found seven studies comparing diverse drugs, doses, and regimen (27 32). Most studies did not report outcomes, such as mortality, rates of UGI bleeding, and pneumonia. Pirenzepine Vs. Famotidine No significant differences were found between groups in one RCT of children who underwent corrective or palliative surgery for congenital heart disease concerning rates of pneumonia and organism cultured from the stomach and from tracheal secretion (32). Ranitidine Vs. Sucralfate One RCT (28) showed that ranitidine had a significant effect in the rate of patients gastric aspirates with mean ph of 4 during 50% compared with sucralfate (one RCT 70 participants; RR, 2.60; 95% CI, ). However, no significant differences were found in the rates of patients with important UGI hemorrhage (28) and macroscopic bleeding, death and pneumonia, and in the duration of mechanical ventilation and pediatric ICU stay (29). Ranitidine Vs. Amalgate Ranitidine was significantly superior to amalgate in the rate of patients gastric aspirates with mean ph of 4 during 50% of study time (one RCT 70 participants; RR, 0.79; 95% CI, ). No significant differences were found between groups in the rates of patients with important UGI hemorrhage and gastrointestinal symptoms, such as nausea, vomiting, or diarrhea (28). Amalgate Vs. Sucralfate One RCT (28) showed that amalgate had a significant effect in the rate of patients gastric aspirates with mean ph of 4 during 50% compared with sucralfate (one RCT 70 participants; RR, 3.30; 95% CI, ). No significant differences were found between groups in the rates of patients with important UGI hemorrhage and gastrointestinal symptoms, such as nausea, vomiting, or diarrhea (28). Ranitidine Vs. Famotidine No significant differences were found between groups in one RCT (31) of critically ill pediatric patients in the rate of patients gastric aspirates with mean ph of 4 during 80% of study time. Other Comparisons No significant differences were found between groups in one RCT (30) of pa- 128 Pediatr Crit Care Med 2010 Vol. 11, No. 1

6 Table 2. Assessment of the risk of bias in randomized s included in the review a (9) Study Sequence Generation Allocation Concealment Blinding of Participants, Personnel, and Outcome Assessors Incomplete Outcome Data/ Withdrawals Free of Selective Reporting? Other Sources of Bias/Commentaries Overall Risk Aanpreung et al (31) Behrens et al (32) Kuusela et al (33) Lacroix et al (26) Lopez-Herce et al (27) Lopez-Herce et al (28) Osteyee et al (29) Yildizdas et al (30) Unclear Unclear No Yes No Yes. Description of baseline characteristics. Unclear risk of bias Unclear Unclear No Yes Unclear Yes. The clinical course of Unclear risk of bias patients in both groups was similar. Similar baseline characteristics. Unclear Unclear Unclear Yes Unclear Yes Unclear risk of bias Yes Unclear Unclear Yes Unclear Yes Unclear risk of bias Unclear Unclear No Yes No No description of baseline High risk of bias characteristics. Unclear Unclear No Unclear No Yes Unclear risk of bias Unclear Unclear No No No No description of baseline characteristics. Yes Unclear No Unclear Unclear Yes. Baseline characteristics and primary diseases in the patients were reported for both groups. High risk of bias Unclear risk of bias Yes, low risk of bias; No, high risk of bias. a According to the Cochrane Collaboration Handbook. Sequence generation: Was the allocation sequence adequately generated? Allocation concealment: Was allocation adequately concealed? Blinding of participants, personnel, and outcome assessors: Was knowledge of the allocated intervention adequately prevented during the study? Incomplete outcome data/withdrawals: Were intention to treat analyses performed? Had participants withdrawn from the study? Free of selective reporting? Other sources of bias: Was sample size calculated? Were inclusion/exclusion criteria and baseline characteristics defined? Were conflicts of interests reported? Figure 2. Meta-analysis of prophylaxis for preventing upper gastrointestinal bleeding (macroscopic or important bleeding) compared with no treatment. M-H, Mantel-Haenszel; CI, confidence interval; df, degrees of freedom. tients who needed mechanical ventilation on admission concerning rates of macroscopic bleeding, deaths, pneumonia, and the duration of mechanical ventilation and pediatric ICU stay when comparing omeprazole vs. ranitidine and omeprazol vs. sucralfate. Ranitidine Versus Ranitidine at Different Doses and Regimen One RCT (27) showed that intravenous ranitidine at 2 mg/kg and 4 mg/kg had a significant effect in the rate of patients gastric aspirates with mean ph of 4 during 80% of study time compared with ranitidine by nasogastric tube (one RCT 20 participants; RR, 0.25; 95% CI, and RR, 0.25; 95% CI, , respectively). Another RCT did not find significant difference in patients gastric aspirates ph when comparing bolus dosing and continuous infusion dosing of 4 mg/kg per day of intravenous ranitidine (29). DISCUSSION The RCTs included in this review have assessed a broad range of treatments that resulted in limited opportunities to describe and pool useful data. Studies available for analysis are a highly heterogeneous group, with different drugs being used and different methods for assessing their efficacy (e.g., some used endoscopy on all patients, others simply monitored nasogastric output for bleeding). Furthermore, because the majority of RCTs had an unclear risk of bias, small sample size, and did not reported relevant outcomes, it was difficult to conclude whether one treatment was more beneficial than the comparator most of the time. Most RCTs focused on secondary outcomes, such as gastric ph control. In addition, methods used for diagnosis of UGI bleeding greatly varied across studies and we could not integrate data for most comparisons. Pooled data of two studies suggested that pediatric patients may benefit from receiving prophylactic treatment for preventing UGI bleeding. There was reasonable evidence that ranitidine is better than no treatment in mechanically ven- Pediatr Crit Care Med 2010 Vol. 11, No

7 Table 3. Summary of relevant findings for primary outcomes of randomized s included in the review a Study Outcome Comparison (n) Relative Risk (95% CI) p Value/Heterogeneity Lopez-Herce et al (28) Lacroix et al (26) Lopez-Herce et al (28) Lopez-Herce et al (28) UGI bleeding (macroscopic or important bleeding) UGI bleeding (macroscopic or important bleeding) UGI bleeding (macroscopic or important bleeding) Treatment vs. (143) vs. no treatment (77) Treatment (162) vs. no treatment or placebo (98) Sucralfate (73) vs. no treatment (77) Kuusela et al (33) Deaths Treatment (141) vs. no treatment (67) Pneumonia Treatment (118) vs. no treatment (42) Kuusela et al (33) Kuusela et al (33) Rate of patients with normal visual endoscopic findings Rate of patients with normal histological endoscopic findings Ranitidine (23) vs. no treatment (25) Ranitidine (23) vs. no treatment (25) 0.38 ( ) a.03; heterogeneity p.35; I 2 33% 0.66 ( ) b ns; heterogeneity p.07; I 2 63% 0.31 ( ) a ns; heterogeneity p.35; I 2 33% 1.24 ( ) a ns 1.11 ( ) ns 3.04 ( ) ( ).01 CI, confidence interval; UGI, upper gastrointestinal; ns, nonsignificant. a Relative risk and 95% CI for dichotomous primary outcomes were calculated by the Mantel-Haenszel fixed-effects model; b relative risk and 95% CI for dichotomous primary outcomes were calculated by the Mantel-Haenszel random-effects model. Table 4. Risk factors significantly associated with gastrointestinal bleeding in severely ill pediatric patients Risk Factor Participants OR or RR (95% CI) Reference Mechanically ventilated NB in PICU OR 4.06 ( ) Kuussela et al (38) 1 15 yrs in PICU OR 5.13 ( ) Nithiwathanapong et al (40) PRISM score yrs in PICU OR 13.4 ( ) Chaibou et al (1) Children in PICU RR 2.87 ( ) Lacroix et al (39) Respiratory failure 3 18 yrs in PICU OR 10.2 ( ) Chaibou et al (1) Coagulopathy 3 18 yrs in PICU OR 9.3 ( ) Chaibou et al (1) Children in PICU RR 5.37 ( ) Lacroix et al (39) Thrombocytopenia 1 15 yrs in PICU OR 2.26 ( ) Nithiwathanapong et al (40) Shock NB 19 yrs in PICU OR ( ) Cochran et al (34) Surgery time 3 hrs NB 19 yrs in PICU OR 3.57 ( ) Cochran et al (34) Trauma NB 19 yrs in Children OR ( ) Cochran et al (34) in PICU RR 2.46 ( ) Lacroix et al (39) Pneumonia Children in PICU RR 3.47 ( ) Lacroix et al (39) Enteral feeding Children in PICU RR 4.16 ( ) Lacroix et al (39) Organ failure Mechanically ventilated RR 2.85 ( ) Deerojanawong et al (35) Corticoid administration NB RR 1.90 ( ) Halliday et al (36) RR 1.74 ( ) Halliday et al (37) OR, odds ratio, RR, relative risk; CI, confidence interval; NB, newborn; PICU, pediatric intensive care unit; PRISM, Pediatric Risk of Mortality. tilated preterm and full-term newborns treated in a neonatal ICU in improving rates of normal gastric mucosal endoscopic findings by visual inspection and histologic specimens (33). In addition, ranitidine, sucralfate, and amalgate were also better than no treatment in improving rates of patients gastric aspirates with mean ph of 4 during 50% of study time (28). However, we found no evidence to support that prophylaxis medication is better than no treatment to decrease the rates of ulcers or erosion or deaths. Furthermore, no evidence was found to support that prophylaxis decreases the duration of mechanical ventilation or pediatric ICU stay. On the other hand, we did not find significant increase in the rates of pneumonia or adverse event. Finally, intravenous ranitidine was superior to ranitidine by nasogastric tube in improving rates of patients with mean ph of 4 during 80% of study time. A meta-analysis evaluating the effect of stress ulcer prophylaxis on gastrointestinal bleeding, pneumonia, and mortality in critically ill adult patients demonstrates that prophylaxis with histamine2- receptor antagonists decreases the occurrence of overt gastrointestinal bleeding (OR, 0.58; 95% CI, ) and clinically important bleeding (OR, 0.44; 95% CI, ). Authors also reported a trend toward an increased risk of pneumonia associated with histamine2-receptor antagonists as compared with no prophylaxis (OR, 1.25; 95% CI, ). However, sucralfate was associated with a lower prevalence of nosocomial pneumonia and reduced mortality rate when compared with antacids and histamine2- receptor antagonists (5). An additional RCT found that ranitidine had a significantly lower rate of clinically important UGI bleeding than sucralfate in 1200 critically ill adult patients requiring mechanical ventilation. Authors also reported no significant differences in the rates of ventilator-associated pneumonia, the duration of the stay in the ICU, or mortality (6). A number of risk factors associated with stress ulcers, gastritis, and gastrointestinal bleeding in severelly ill pediatric patients have been described in observational studies (Table 4) (1, 34 40). A cohort study found that respiratory failure, 130 Pediatr Crit Care Med 2010 Vol. 11, No. 1

8 coagulopathy, and a Pediatric Risk of Mortality Score of 10 were independent risk factors for clinically significant upper GI bleeding, using multivariate analysis. Based on those findings, authors recommended that prophylaxis to prevent UGI bleeding may be limited to patients who present with at least two risk factors (1). We have produced an updated coverage of RCTs of prophylactic treatments for stress ulcers in children by summarizing the best available data. Although pooled data of two studies suggested that critically ill pediatric patients may benefit from receiving prophylactic treatment for preventing UGI bleeding, the overall quality of the evidence is low, leading to a weak recommendation (using GRADE approach) (10). Although limited evidence is available, some of the drugs studied (histamine2 receptor antagonists, sucralfate, amalgate) have been replaced in clinical use by proton pump inhibitors. However, only one study including patients treated with omeprazole was found (30). We need more evidence demonstrating the effectiveness and safety of different prophylactic drugs and improved design and reporting of RCTs. We should also investigate the use of proton pump inhibitors in children. ACKNOWLEDGMENT We thank Dr. Rodrigo Pardo of the Research Institute of the National University of Colombia for instructive commentaries to improve this manuscript. REFERENCES 1. Chaïbou M, Tucci M, Dugas MA, et al: Clinically significant upper gastrointestinal bleeding acquired in a pediatric intensive care unit: A prospective study. Pediatrics 1998; 102: Cook DJ, Griffith LE, Walter SD, et al: The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care 2001; 5: Erstad BL, Barletta JF, Jacobi J, et al: Survey of stress ulcer prophylaxis. Crit Care 1999; 3: Cook DJ, Fuller HD, Guyatt GH, et al: Risk factors for gastrointestinal bleeding in critically ill patients. NEnglJMed1994; 330: Cook DJ, Reeve BK, Guyatt GH, et al: Stress ulcer prophylaxis in critically ill patients: Resolving discordant meta-analyses. JAMA 1996; 275: Cook DJ, Guyatt GH, Marshall J, et al: A comparison of sucralfate and ranitidine for prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. N Engl J Med 1998; 338: Messori A, Trippoli S, Vaiani M, et al: Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: Meta-analysis of randomised s. BMJ 2000; 321: Spirt MJ, Stanley S: Update on stress ulcer prophylaxis in critically ill patients. Crit Care Nurse 2006; 26: Higgins JPT, Green S (Eds). Cochrane Handbook for Systematic Reviews of Interventions Version [Updated February 2008]. The Cochrane Collaboration, Available at: Accessed November 23, Guyatt GH, Oxman AD, Vist G, et al: Rating quality of evidence and strength of recommendations GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: Golder S, McIntosh HM, Duffy S, et al: Developing efficient search strategies to identify reports of adverse effects in MEDLINE and EMBASE. Health Info Libr J 2006; 23: Agarwal AK, Saili A, Pandey KK, et al: Role of cimetidine in prevention and treatment of stress induced gastric bleeding in neonates. Indian Pediatr 1990; 27: Bonten MJ, Gaillard CA, van Tiel FH, et al: Continuous enteral feeding counteracts preventive measures for gastric colonization in intensive care unit patients. Crit Care Med 1994; 22: Cothran DS, Borowitz SM, Sutphen JL, et al: Alteration of normal gastric flora in neonates receiving ranitidine. J Perinatol 1997; 17: Eddleston JM, Booker PD, Green JR: Use of ranitidine in children undergoing cardiopulmonary bypass. Crit Care Med 1989; 17: Gedeit RG, Weigle CG, Havens PL, et al: Control and variability of gastric ph in critically ill children. Crit Care Med 1993; 21: Haizlip JA, Lugo RA, Cash JJ, et al: Failure of nasogastric omeprazole suspension in pediatric intensive care patients. Pediatr Crit Care Med 2005; 6: Harrison AM, Lugo RA, Vernon DD: Gastric ph control in critically ill children receiving intravenous ranitidine. Crit Care Med 1998; 26: Kaufman SS, Lyden ER, Brown CR, et al: Omeprazole therapy in pediatric patients after liver and intestinal transplantation. JPediatrGastroenterol Nutr 2002; 34: Kentrup H, Skopnik H, Wolter L, et al: Antacids for postoperative prevention of stress ulcer in infants: A dose finding study. Klin Padiatr 1996; 208: Kuusela AL: Long-term gastric ph monitoring for determining optimal dose of ranitidine for critically ill preterm and term neonates. Arch Dis Child Fetal Neonatal Ed 1998; 78: Lloyd CW, Martin WJ, Taylor BD, et al: Pharmacokinetics and pharmacodynamics of cimetidine and metabolites in critically ill children. J Pediatr 1985; 107: Lugo RA, Harrison AM, Cash J, et al: Pharmacokinetics and pharmacodynamics of ranitidine in critically ill children. Crit Care Med 2001; 29: Wiest DB, O Neal W, Reigart JR, et al: Pharmacokinetics of ranitidine in critically ill infants. Dev Pharmacol Ther 1989; 12: Hencz P, Baltás B, Tekulics P: Cimetidine therapy of stress ulcer caused by lifethreatening illnesses in children. Orv Hetil 1984; 125: Lacroix J, Infante-Rivard C, Gauthier M, et al: Upper gastrointestinal tract bleeding acquired in a pediatric intensive care unit: Prophylaxis trial with cimetidine. J Pediatr 1986; 108: Lopez-Herce Cid J, Albajara Velasco L, et al: Ranitidine prophylaxis in acute gastric mucosal damage in critically ill pediatric patients. Crit Care Med 1988; 16: López-Herce J, Dorao P, Elola P, et al: Frequency and prophylaxis of upper gastrointestinal hemorrhage in critically ill children: A prospective study comparing the efficacy of almagate, ranitidine, and sucralfate. The Gastrointestinal Hemorrhage Study Group. Crit Care Med 1992; 20: Osteyee JL, Banner W Jr: Effects of two dosing regimens of intravenous ranitidine on gastric ph in critically ill children. Am J Crit Care 1994; 3: Yildizdas D, Yapicioglu H, Yilmaz HL: Occurrence of ventilator-associated pneumonia in mechanically ventilated pediatric intensive care patients during stress ulcer prophylaxis with sucralfate, ranitidine, and omeprazole. J Crit Care 2002; 17: Aanpreung P, Vanprapar N, Susiva C, et al: A randomized clinical trial comparing the efficacy of ranitidine and famotidine on intragastric acidity in critically ill pediatric patients. J Med Assoc Thai 1998; 81: Behrens R, Hofbeck M, Singer H, et al: Frequency of stress lesions of the upper gastrointestinal tract in paediatric patients after cardiac surgery: Effects of prophylaxis. Br Heart J 1994; 72: Kuusela AL, Ruuska T, Karikoski R, et al: A randomized, controlled study of prophylactic ranitidine in preventing stress-induced gastric mucosal lesions in neonatal intensive care unit patients. Crit Care Med 1997; 25: Cochran EB, Phelps SJ, Tolley EA, et al: Prevalence of, and risk factors for, upper gastrointestinal tract bleeding in critically ill pediatric patients. Crit Care Med 1992; 20: Deerojanawong J, Peongsujarit D, Vivatvakin B, et al: Incidence and risk factors of upper gastrointestinal bleeding in mechanically ventilated children. Pediatr Crit Care Med 2009; 10: Halliday HL, Ehrenkranz RA, Doyle LW: Early postnatal ( 96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; 1:CD Halliday HL, Ehrenkranz RA, Doyle LW: Moderately early (7 14 days) postnatal corti- Pediatr Crit Care Med 2010 Vol. 11, No

9 costeroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; 1:CD Kuusela AL, Mäki M, Ruuska T, et al: Stressinduced gastric findings in critically ill newborn infants: Frequency and risk factors. Intensive Care Med 2000; 26: Lacroix J, Nadeau D, Laberge S, et al: Frequency of upper gastrointestinal bleeding in a pediatric intensive care unit. Crit Care Med 1992; 20: Nithiwathanapong C, Reungrongrat S, Ukarapol N: Prevalence and risk factors of stress-induced gastrointestinal bleeding in critically ill children. World J Gastroenterol 2005; 11: APPENDIX A Search Strategy for PubMed (Randomized [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR ( clinical trial [tw]) OR ((singl* [tw] OR doulb* [tw] OR tripl* OR trebl* [tw]) AND (mask* [tw] OR blind* [tw])) OR ( latin square [tw]) OR placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] OR evaluation studies [pt] OR follow-up studies [mh] OR prospective studies [mh] OR crossover studies [mh] OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animal [mh] NOT human [mh]) AND ( Peptic Ulcer Perforation [Mesh] OR Peptic Ulcer [Mesh] OR Duodenal Ulcer [Mesh] OR Stomach Ulcer [Mesh] OR Peptic Ulcer Hemorrhage [Mesh] OR Curling s ulcer [tw] OR ((ulcer* [tw] OR bleeding [tw] OR hemorrhage [tw] OR hemorrhage [tw] OR ulceration [tw]) AND (Peptic [tw] OR Duodenal [tw] OR Stomach [tw] OR gastric [tw] OR gastrointestinal [tw] OR gastro-intestinal [tw]))) AND (stress [tw] OR critically ill [tw] OR intensive care [tw] OR serious burns [tw] OR mechanical ventilation [tw] OR ventilator[tw] OR Critical Illness [mh] OR Ventilators, Mechanical [tw] OR severely injured [tw] OR PICU [tw] OR ICU [tw]) AND ( Anti-Ulcer Agents [Mesh] OR prophylaxis [tw] OR prevention [tw] OR prevent [tw] OR Antacid* [tw] OR Histamine H2 Antagonists [tw] OR sucralfate [tw] OR Proton-pump inhibitors [tw] OR cimetidine [tw] OR omeprazole [tw] OR Esomeprazole [tw] OR ranitidine [tw] OR Cisapride [tw] OR Famotidine [tw] OR lansoprazole [tw] OR pantoprazole [tw] OR rabeprazole [tw] OR Acid suppression [tw]) AND (Child [mh] OR children [tw] OR pediatric* [tw] OR pediatric* [tw] OR Preschool OR Infant [mh] OR infant* [tw] OR newborn [tw] OR perinatal [tw] OR neonatal [tw] OR preterm [tw] OR postnatal [tw] OR premature [tw] OR childhood [tw] OR neonate* [tw]). 132 Pediatr Crit Care Med 2010 Vol. 11, No. 1

VUMC Multidisciplinary Surgical Critical Care

VUMC Multidisciplinary Surgical Critical Care VUMC Multidisciplinary Surgical Critical Care Gastrointestinal Stress Ulcer Prophylaxis Guideline: Background: Work by Cooke and colleagues ascribed the risk of overt bleeding to be 4.4% and clinically

More information

Chapter 34. Prevention of Clinically Significant Gastrointestinal Bleeding in Intensive Care Unit Patients

Chapter 34. Prevention of Clinically Significant Gastrointestinal Bleeding in Intensive Care Unit Patients Chapter 34. Prevention of Clinically Significant Gastrointestinal Bleeding in Intensive Care Unit Patients Daniel D. Dressler, MD Mark V. Williams, MD Kimberly Rask, MD, PhD Emory University Schools of

More information

Optimal Drugs for ICU Stress Ulcer Prophylaxis: Other. Grand Rounds Monday August 9, 2010 Teresa Jones R2

Optimal Drugs for ICU Stress Ulcer Prophylaxis: Other. Grand Rounds Monday August 9, 2010 Teresa Jones R2 Optimal Drugs for ICU Stress Ulcer Prophylaxis: Other Grand Rounds Monday August 9, 2010 Teresa Jones R2 Outline Options besides PPIs Comparison to PPIs Negative Effects of PPIs Conclusion Do we really

More information

Stressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU

Stressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU Stressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds November 8, 2016 2016 MFMER slide-1 Objectives Identify the significance

More information

Do PPIs Reduce Bleeding in ICU? Revisiting Stress Ulcer Prophylaxis. Deborah Cook

Do PPIs Reduce Bleeding in ICU? Revisiting Stress Ulcer Prophylaxis. Deborah Cook Do PPIs Reduce Bleeding in ICU? Revisiting Stress Ulcer Prophylaxis Deborah Cook ICU-Acquired Upper GI Bleeding Case series of 300 ICU patients describing stressrelated erosive syndrome Frequent Fatal

More information

STRESS ULCER PROPHYLAXIS SUMMARY

STRESS ULCER PROPHYLAXIS SUMMARY DISCLAIMER: These guidelines were prepared jointly by the Surgical Critical Care and Medical Critical Care Services at Orlando Regional Medical Center. They are intended to serve as a general statement

More information

Audit: Use of stress ulcer prophylaxis in critically ill patients

Audit: Use of stress ulcer prophylaxis in critically ill patients Audit: Use of stress ulcer prophylaxis in critically ill patients Dr. Sinan Bahlool Consultant, Anaesthetics & ITU Dr. Krushna Patel FY1 Dr. Andrew Baigey FY1 BACKGROUND Stress ulcer prophylaxis is prescribed

More information

Proton Pump Inhibitors- Questions & Controversies. Farah Kablaoui, PharmD, BCPS, BCCCP

Proton Pump Inhibitors- Questions & Controversies. Farah Kablaoui, PharmD, BCPS, BCCCP Proton Pump Inhibitors- Questions & Controversies Farah Kablaoui, PharmD, BCPS, BCCCP Disclosure Information Proton Pump Inhibitors: Questions & Controversies Farah Kablaoui I have no financial relationship

More information

Deep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H

Deep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H Deep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H Authors' objectives To systematically review the incidence of deep vein

More information

Database of Abstracts of Reviews of Effects (DARE) Produced by the Centre for Reviews and Dissemination Copyright 2017 University of York.

Database of Abstracts of Reviews of Effects (DARE) Produced by the Centre for Reviews and Dissemination Copyright 2017 University of York. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling Brown

More information

ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis

ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis A SHP REPORT Stress ulcer prophylaxis ASHP Report ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis DEVELOPED THROUGH THE ASHP COMMISSION ON THERAPEUTICS AND APPROVED BY THE ASHP BOARD OF DIRECTORS

More information

Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist.

Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:

More information

SWISS SOCIETY OF NEONATOLOGY. Spontaneous intestinal perforation or necrotizing enterocolitis?

SWISS SOCIETY OF NEONATOLOGY. Spontaneous intestinal perforation or necrotizing enterocolitis? SWISS SOCIETY OF NEONATOLOGY Spontaneous intestinal perforation or necrotizing enterocolitis? June 2004 2 Stocker M, Berger TM, Neonatal and Pediatric Intensive Care Unit, Children s Hospital of Lucerne,

More information

Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist

Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist Disclosures I have no actual or potential conflicts of interest to report in relation to this

More information

CYP2C19-Proton Pump Inhibitors

CYP2C19-Proton Pump Inhibitors CYP2C19-Proton Pump Inhibitors Cameron Thomas, Pharm.D. PGY2 Clinical Pharmacogenetics Resident St. Jude Children s Research Hospital February 1, 2018 Objectives: CYP2C19-PPI Implementation Review the

More information

On-Call Upper GI Bleeding. Upper Gastrointestinal Bleeding

On-Call Upper GI Bleeding. Upper Gastrointestinal Bleeding On-Call Upper GI Bleeding John R Saltzman MD, FACG Director of Endoscopy Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical School Upper Gastrointestinal Bleeding 300,000000 hospitalizations/year

More information

PICC or peripheral intravenous catheter?

PICC or peripheral intravenous catheter? PICC or peripheral intravenous catheter? B.S. Niël-Weise 1, P.J. van den Broek 2 1 Dutch Infection Prevention Working Party, Leiden, The Netherlands 2 Department of Infectious Diseases, Leiden University

More information

Significant Upper Gi Bleeding In Critically Ill Patients

Significant Upper Gi Bleeding In Critically Ill Patients ISPUB.COM The Internet Journal of Gastroenterology Volume 5 Number 2 Significant Upper Gi Bleeding In Critically Ill Patients M Khoshbaten, H Farzin, E Fattahi, M Entezarie Asl Citation M Khoshbaten, H

More information

Cochrane Pregnancy and Childbirth Group Methodological Guidelines

Cochrane Pregnancy and Childbirth Group Methodological Guidelines Cochrane Pregnancy and Childbirth Group Methodological Guidelines [Prepared by Simon Gates: July 2009, updated July 2012] These guidelines are intended to aid quality and consistency across the reviews

More information

Urate Lowering Efficacy of Febuxostat Versus Allopurinol in Hyperuricemic Patients with Gout

Urate Lowering Efficacy of Febuxostat Versus Allopurinol in Hyperuricemic Patients with Gout Philippine Journal of Internal Medicine Meta-Analysis Urate Lowering Efficacy of Febuxostat Versus Allopurinol in Hyperuricemic Patients with Gout Erika Bianca S. Villazor-Isidro, M.D.*; John Carlo G.

More information

Drug Class Review on Proton Pump Inhibitors

Drug Class Review on Proton Pump Inhibitors Drug Class Review on Proton Pump Inhibitors Final Report Update 4 July 2006 Original Report Date: November 2002 Update 1 Report Date: April 2003 Update 2 Report Date: April 2004 Update 3 Report Date: May

More information

Copyright 2012 Informa UK Limited

Copyright 2012 Informa UK Limited Journal of Drug Assessment Vol. 1, 2012, 24 29 2155-6660 Article 0007.R1/655816 doi:10.3109/21556660.2012.655816 All rights reserved: reproduction in whole or part not permitted Original article Acid reducing

More information

Stress Ulcer Prophylaxis In The ICU. Scott W. Wolf Anesthesiology Critical Care Medicine

Stress Ulcer Prophylaxis In The ICU. Scott W. Wolf Anesthesiology Critical Care Medicine Stress Ulcer Prophylaxis In The ICU Scott W. Wolf Anesthesiology Critical Care Medicine Some history Stress Ulceration described in ICU patients as long as 45 years ago Patients had a constellation of

More information

Hazards and Benefits of Postnatal Steroids. David J. Burchfield, MD Professor and Chief, Neonatology University of Florida

Hazards and Benefits of Postnatal Steroids. David J. Burchfield, MD Professor and Chief, Neonatology University of Florida Hazards and Benefits of Postnatal Steroids David J. Burchfield, MD Professor and Chief, Neonatology University of Florida Disclosures I have no financial affiliations or relationships to disclose. I will

More information

Effective Health Care

Effective Health Care Effective Health Care Comparative Effectiveness of Management Strategies for Gastroesophageal Reflux Disease Executive Summary Background Gastroesophageal reflux disease (GERD), defined as weekly heartburn

More information

GASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali

GASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers

More information

Gastric Ulcer Prophylaxis in the Critically Ill Equine Neonate ( 6-Nov-2001 )

Gastric Ulcer Prophylaxis in the Critically Ill Equine Neonate ( 6-Nov-2001 ) In: Recent Advances in Equine Neonatal Care, P. A. Wilkins and J. E. Palmer (Eds.) Publisher: International Veterinary Information Service (www.ivis.org), Ithaca, New York, USA. Gastric Ulcer Prophylaxis

More information

PROSPERO International prospective register of systematic reviews

PROSPERO International prospective register of systematic reviews PROSPERO International prospective register of systematic reviews Prophylactic cranial irradiation in patients with non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled

More information

Back to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill

Back to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill Back to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill Joe Palumbo PGY-2 Critical Care Pharmacy Resident Buffalo General Medical Center Disclosures

More information

SECTION 1: INCLUSION, EXCLUSION & RANDOMISATION INFORMATION

SECTION 1: INCLUSION, EXCLUSION & RANDOMISATION INFORMATION SECTION 1: INCLUSION, EXCLUSION & RANDOMISATION INFORMATION DEMOGRAPHIC INFORMATION Given name Family name Date of birth Consent date Gender Female Male Date of surgery INCLUSION & EXCLUSION CRITERIA YES

More information

Lies, damn lies, & clinical trials. Paul Young

Lies, damn lies, & clinical trials. Paul Young Lies, damn lies, & clinical trials Paul Young Base rate neglect statistical power probability of detecting a difference if one exists P of

More information

Patent Ductus Arteriosus: Philosophy or Pathology?

Patent Ductus Arteriosus: Philosophy or Pathology? Patent Ductus Arteriosus: Philosophy or Pathology? Disclosure Ray Sato, MD is a speaker for Prolacta Biosciences, Inc. This presentation will discuss off-label uses of acetaminophen and ibuprofen. RAY

More information

5.3 Strategies to Optimize Delivery and Minimize Risks of EN: Small Bowel Feeding vs. Gastric February 2014

5.3 Strategies to Optimize Delivery and Minimize Risks of EN: Small Bowel Feeding vs. Gastric February 2014 5.3 Strategies to Optimize Delivery and Minimize Risks of EN: Small Bowel Feeding vs. Gastric February 2014 2013 Recommendation: Based on 15 level 2 studies, small bowel feeding compared to gastric feeding

More information

Web appendix: Supplementary data

Web appendix: Supplementary data Web appendix: Supplementary data Azad MA, Coneys JG, Kozyrskyj AL, Field CJ, Ramsey CD, Becker AB, Friesen C, Abou-Setta AM, Zarychanski R. Probiotic supplementation during pregnancy or infancy for the

More information

Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding (Review)

Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding (Review) Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding (Review) Sreedharan A, Martin J, Leontiadis GI, Dorward S, Howden CW, Forman D, Moayyedi P This

More information

Anticoagulants are a contributing factor. Other causes are Mallory-Weiss tears, AV malformations, and malignancy and aorto-enteric fistula.

Anticoagulants are a contributing factor. Other causes are Mallory-Weiss tears, AV malformations, and malignancy and aorto-enteric fistula. Upper GI Bleeding EMU2018 Dr. Walter Himmel MD Incidence: In non-cirrhotics, the commonest causes are peptic ulcer disease (50%) followed by erosive gastritis. In cirrhotic patients, variceal bleeding

More information

Minimal Enteral Nutrition

Minimal Enteral Nutrition Abstract Minimal Enteral Nutrition Although parenteral nutrition has been used widely in the management of sick very low birth weight infants, a smooth transition to the enteral route is most desirable.

More information

Supplemental Information

Supplemental Information FROM THE AMERICAN ACADEMY OF PEDIATRICS Supplemental Information SUPPLEMENTAL FIGURE 2 Forest plot of all included RCTs using a random-effects model and M-H statistics with the outcome of hyponatremia

More information

Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library)

Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library) A systematic review of smoking cessation and relapse prevention interventions in parents of babies admitted to a neonatal unit (after delivery) Divya Nelson, Sarah Gentry, Caitlin Notley, Henry White,

More information

Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding (Review)

Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding (Review) Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding (Review) Sreedharan A, Martin J, Leontiadis GI, Dorward S, Howden CW, Forman D, Moayyedi P This

More information

Intragastric ph With Oral vs Intravenous Bolus Plus Infusion Proton- Pump Inhibitor Therapy in Patients With Bleeding Ulcers

Intragastric ph With Oral vs Intravenous Bolus Plus Infusion Proton- Pump Inhibitor Therapy in Patients With Bleeding Ulcers Intragastric ph With Oral vs Intravenous Bolus Plus Infusion Proton- Pump Inhibitor Therapy in Patients With Bleeding Ulcers LOREN LAINE, ABBID SHAH, and SHAHROOZ BEMANIAN Division of Gastrointestinal

More information

5.3 Strategies to Optimize Delivery and Minimize Risks of EN: Small Bowel Feeding vs. Gastric May 2015

5.3 Strategies to Optimize Delivery and Minimize Risks of EN: Small Bowel Feeding vs. Gastric May 2015 5.3 Strategies to Optimize Delivery and Minimize Risks of EN: Small Bowel Feeding vs. Gastric May 2015 2015 Recommendation: Based on 16 level 2 studies, small bowel feeding compared to gastric feeding

More information

Noah Hillman M.D. IPOKRaTES Conference Guadalajaira, Mexico August 23, 2018

Noah Hillman M.D. IPOKRaTES Conference Guadalajaira, Mexico August 23, 2018 Postnatal Steroids Use for Bronchopulmonary Dysplasia in 2018 + = Noah Hillman M.D. IPOKRaTES Conference Guadalajaira, Mexico August 23, 2018 AAP Policy Statement - 2002 This statement is intended for

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium esomeprazole, 40mg vial of powder for solution for intravenous injection or infusion (Nexium I.V. ) No. (578/09) AstraZeneca 09 October 2009 The Scottish Medicines Consortium

More information

Efficacy of Breast Milk Gastric Lavage in Preterm Neonates. Archana B. Patel and Samiuddin Shaikh

Efficacy of Breast Milk Gastric Lavage in Preterm Neonates. Archana B. Patel and Samiuddin Shaikh Research Papers Efficacy of Breast Milk Gastric Lavage in Preterm Neonates Archana B. Patel and Samiuddin Shaikh From the Department of Pediatrics and Clinical Epidemiology Unit, Indira Gandhi Medical

More information

A bleeding ulcer: What can the GP do? Gastrointestinal bleeding is a relatively common. How is UGI bleeding manifested? Who is at risk?

A bleeding ulcer: What can the GP do? Gastrointestinal bleeding is a relatively common. How is UGI bleeding manifested? Who is at risk? Focus on CME at the University of British Columbia A bleeding ulcer: What can the GP do? By Robert Enns, MD, FRCP Gastrointestinal bleeding is a relatively common disorder affecting thousands of Canadians

More information

What is the Role of Albumin in Sepsis? An Evidenced Based Affair. Justin Belsky MD PGY3 2/6/14

What is the Role of Albumin in Sepsis? An Evidenced Based Affair. Justin Belsky MD PGY3 2/6/14 What is the Role of Albumin in Sepsis? An Evidenced Based Affair Justin Belsky MD PGY3 2/6/14 Microcirculation https://www.youtube.com/watch?v=xao1gsyur7q Capillary Leak in Sepsis Asking the RIGHT Question

More information

Gastroduodenal Stress Ulceration. Bryan Woolridge POS Rounds 29 October 2003

Gastroduodenal Stress Ulceration. Bryan Woolridge POS Rounds 29 October 2003 Gastroduodenal Stress Ulceration Bryan Woolridge POS Rounds 29 October 2003 Objectives Define entity Etiology Differentiation of UGI ulcers Pathophysiology Identify population at risk/risk factors Clinical

More information

PFIZER INC. Study Center(s): A total of 6 centers took part in the study, including 2 in France and 4 in the United States.

PFIZER INC. Study Center(s): A total of 6 centers took part in the study, including 2 in France and 4 in the United States. PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA

5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA 5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA Background RCTs investigating the efficacy of aminosalicylates for

More information

PROSPERO International prospective register of systematic reviews

PROSPERO International prospective register of systematic reviews PROSPERO International prospective register of systematic reviews High-dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents and young adults with first

More information

Famotidine Extended Abstracts

Famotidine Extended Abstracts Famotidine Extended Abstracts I) Primary literature Summary Ciccone, Decktor, et. al. Efficacy and tolerability of famotidine in preventing heartburn and related symptoms of upper gastrointestinal discomfort.

More information

In 1970, Skillman and Silen (1) reported a clinical syndrome

In 1970, Skillman and Silen (1) reported a clinical syndrome Feature Articles Proton Pump Inhibitors Versus Histamine 2 Receptor Antagonists for Stress Ulcer Prophylaxis in Critically Ill Patients: A Systematic Review and Meta-Analysis* Waleed Alhazzani, MD 1 ;

More information

Intermittent vs Continuous Proton Pump Inhibitor Therapy for High-Risk Bleeding Ulcers A Systematic Review and Meta-analysis

Intermittent vs Continuous Proton Pump Inhibitor Therapy for High-Risk Bleeding Ulcers A Systematic Review and Meta-analysis Research Original Investigation Intermittent vs Continuous Proton Pump Inhibitor Therapy for High-Risk Bleeding Ulcers A Systematic Review and Meta-analysis Hamita Sachar, MD; Keta Vaidya, MD; Loren Laine,

More information

Study population The study population comprised hypothetical patients with gastric and duodenal ulcer.

Study population The study population comprised hypothetical patients with gastric and duodenal ulcer. Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan Ikeda S, Tamamuro T, Hamashima C, Asaka M Record Status This is a critical

More information

VAP Prevention bundles

VAP Prevention bundles VAP Prevention bundles Dr. Shafiq A.Alimad MD Head of medical department at USTH YICID workshop, 15-12-2014 Care Bundles What are they & why use them? What are Care Bundles? Types of Care Bundles available

More information

Surgery for Complications of Peptic Ulcer Disease (Definitive Treatment)

Surgery for Complications of Peptic Ulcer Disease (Definitive Treatment) Surgery for Complications of Peptic Ulcer Disease (Definitive Treatment) Amid Keshavarzi, MD UCHSC Grand Round 3/20/2006 Department of Surgery Introduction Epidemiology Pathophysiology Clinical manifestation

More information

Critical Appraisal Practicum. Fabio Di Bello Medical Implementation Manager

Critical Appraisal Practicum. Fabio Di Bello Medical Implementation Manager Critical Appraisal Practicum Fabio Di Bello Medical Implementation Manager fdibello@ebsco.com What we ll talk about today: DynaMed process for appraising randomized trials and writing evidence summaries

More information

Steroid in Paediatric Sepsis. Dr Pon Kah Min Hospital Pulau Pinang

Steroid in Paediatric Sepsis. Dr Pon Kah Min Hospital Pulau Pinang Steroid in Paediatric Sepsis Dr Pon Kah Min Hospital Pulau Pinang Contents Importance of steroid in sepsis Literature Review for adult studies Literature Review for paediatric studies Conclusions. Rationale

More information

11/19/2012. Comparison between PPIs G CELL. Risk ratio (95% CI) Patient subgroup. gastrin. S-form of omeprazole. Acid sensitive. coated.

11/19/2012. Comparison between PPIs G CELL. Risk ratio (95% CI) Patient subgroup. gastrin. S-form of omeprazole. Acid sensitive. coated. REGULATION OF GASTRIC ACID SECRETION Comparison between PPIs Omeprazole Lansoprazole Rabeprazole Pantoprazole Esomeprazole gastrin G CELL + Acid sensitive Yes T1/2 30-60 minutes Main elimination Enteric

More information

A Systematic Review and Meta-Analysis of Pre-Transfusion Hemoglobin Thresholds for Allogeneic Red Blood Cell Transfusions

A Systematic Review and Meta-Analysis of Pre-Transfusion Hemoglobin Thresholds for Allogeneic Red Blood Cell Transfusions A Systematic Review and Meta-Analysis of Pre-Transfusion Hemoglobin Thresholds for Allogeneic Red Blood Cell Transfusions Authors: Lesley J.J. Soril 1,2, MSc; Laura E. Leggett 1,2, MSc; Joseph Ahn, MSc

More information

Policy Evaluation: Proton Pump Inhibitors (PPIs)

Policy Evaluation: Proton Pump Inhibitors (PPIs) Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Is Rabeprazole A Safe Treatment for Gastroesophageal Reflux Disease in Children Ages 1-16 years?

Is Rabeprazole A Safe Treatment for Gastroesophageal Reflux Disease in Children Ages 1-16 years? Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Is Rabeprazole A Safe Treatment for Gastroesophageal

More information

Approach to Severe Sepsis. Jan Hau Lee, MBBS, MRCPCH. MCI Children s Intensive Care Unit KK Women s and Children's Hospital, Singapore

Approach to Severe Sepsis. Jan Hau Lee, MBBS, MRCPCH. MCI Children s Intensive Care Unit KK Women s and Children's Hospital, Singapore Approach to Severe Sepsis Jan Hau Lee, MBBS, MRCPCH. MCI Children s Intensive Care Unit KK Women s and Children's Hospital, Singapore 1 2 No conflict of interest Overview Epidemiology of Pediatric Severe

More information

Peptic ulcer disease Disorders of the esophagus

Peptic ulcer disease Disorders of the esophagus Peptic ulcer disease Disorders of the esophagus Peptic ulcer disease Burning epigastric pain Exacerbated by fasting Improved with meals Ulcer: disruption of mucosal integrity >5 mm in size, with depth

More information

Lumbar puncture. Invasive procedure: diagnostic or therapeutic. The subarachnoid space 4-13 ys: ml Replenished: 4-6 h Routine LP (3-5 ml): <1h

Lumbar puncture. Invasive procedure: diagnostic or therapeutic. The subarachnoid space 4-13 ys: ml Replenished: 4-6 h Routine LP (3-5 ml): <1h Lumbar puncture Lumbar puncture Invasive procedure: diagnostic or therapeutic. The subarachnoid space 4-13 ys: 65-150ml Replenished: 4-6 h Routine LP (3-5 ml):

More information

Gastrointestinal Safety of Coxibs and Outcomes Studies: What s the Verdict?

Gastrointestinal Safety of Coxibs and Outcomes Studies: What s the Verdict? Vol. 23 No. 4S April 2002 Journal of Pain and Symptom Management S5 Proceedings from the Symposium The Evolution of Anti-Inflammatory Treatments in Arthritis: Current and Future Perspectives Gastrointestinal

More information

Drain versus no-drain after gastrectomy for patients with advanced gastric cancer Student EBM presentations

Drain versus no-drain after gastrectomy for patients with advanced gastric cancer Student EBM presentations Drain versus no-drain after gastrectomy for patients with advanced gastric cancer Student EBM presentations Selali Fiamanya & Jawaad Farrukh University of Oxford October 2014 The question Mr X is a 56

More information

PROSPERO International prospective register of systematic reviews

PROSPERO International prospective register of systematic reviews PROSPERO International prospective register of systematic reviews Closed reduction methods for acute anterior shoulder dislocation [Cochrane Protocol] Kanthan Theivendran, Raj Thakrar, Subodh Deshmukh,

More information

Evidence Summary For the Ghana Essential Medicines Committee

Evidence Summary For the Ghana Essential Medicines Committee Evidence Summary For the Ghana Essential Medicines Committee Title: Caffeine Citrate for treating apnoea in preterm infants Formulation: 1. Injection: 20 mg/ml (equivalent to 10 mg caffeine base/ml) 2.

More information

COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION

COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,

More information

Empirical evidence on sources of bias in randomised controlled trials: methods of and results from the BRANDO study

Empirical evidence on sources of bias in randomised controlled trials: methods of and results from the BRANDO study Empirical evidence on sources of bias in randomised controlled trials: methods of and results from the BRANDO study Jonathan Sterne, University of Bristol, UK Acknowledgements: Tony Ades, Bodil Als-Nielsen,

More information

GATE CAT Intervention RCT/Cohort Studies

GATE CAT Intervention RCT/Cohort Studies GATE: a Graphic Approach To Evidence based practice updates from previous version in red Critically Appraised Topic (CAT): Applying the 5 steps of Evidence Based Practice Using evidence about interventions

More information

Routine endotracheal cultures for the prediction of sepsis in ventilated babies

Routine endotracheal cultures for the prediction of sepsis in ventilated babies Archives of Disease in Childhood, 1989, 64, 34-38 Routine endotracheal cultures for the prediction of sepsis in ventilated babies T A SLAGLE, E M BIFANO, J W WOLF, AND S J GROSS Department of Pediatrics,

More information

A. Incorrect! Histamine is a secretagogue for stomach acid, but this is not the only correct answer.

A. Incorrect! Histamine is a secretagogue for stomach acid, but this is not the only correct answer. Pharmacology - Problem Drill 21: Drugs Used To Treat GI Disorders No. 1 of 10 1. Endogenous secretagogues for stomach acid include: #01 (A) Histamine (B) Gastrin (C) PGE1 (D) A and B (E) A, B and C Histamine

More information

Effective Health Care Program

Effective Health Care Program Comparative Effectiveness Review Number 57 Effective Health Care Program Methods for Insulin Delivery and Glucose Monitoring: Comparative Effectiveness Executive Summary Background Diabetes mellitus is

More information

Nonsteroidal anti-inflammatory drugs and perioperative bleeding in paediatric tonsillectomy (Review)

Nonsteroidal anti-inflammatory drugs and perioperative bleeding in paediatric tonsillectomy (Review) Nonsteroidal anti-inflammatory drugs and perioperative bleeding in paediatric tonsillectomy (Review) Lewis SR, Nicholson A, Cardwell ME, Siviter G, Smith AF This is a reprint of a Cochrane review, prepared

More information

SUCRALFATE ISELPIN 1 g Tablet

SUCRALFATE ISELPIN 1 g Tablet 1.0 PHARMACOLOGIC CATEGORY CYTOPROTECTOR 2.0 DESCRIPTION SUCRALFATE ISELPIN 1 g Tablet Sucralfate is a white, amorphous powder which is soluble in strong acids and in alkalis but practically insoluble

More information

Reflux of gastric contents, particularly acid, into the esophagus

Reflux of gastric contents, particularly acid, into the esophagus Heartburn Reflux of gastric contents, particularly acid, into the esophagus Patient assessment with GERD 1-signs and symptoms The hallmark of typical symptom of GERD is heartburn (restrosternal),acid regurgitation,

More information

National Digestive Diseases Information Clearinghouse

National Digestive Diseases Information Clearinghouse Gastritis National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is gastritis? Gastritis is a condition in which the stomach

More information

Specific Care Question : Question Originator: Plain Language Summary from The Office of Evidence Based Practice: Conditional Recommendation

Specific Care Question : Question Originator: Plain Language Summary from The Office of Evidence Based Practice: Conditional Recommendation Ketorolac for Refractory Migraine in the ED Specific Care Question : In the pediatric patient diagnosed with refractory migraine is ketorolac an effective treatment? Question Originator: Migraine Therapy

More information

The usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials.

The usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials. Name Gasec - 2 Gastrocaps Composition Gasec-20 Gastrocaps Each Gastrocaps contains: Omeprazole 20 mg (in the form of enteric-coated pellets) Properties, effects Proton Pump Inhibitor Omeprazole belongs

More information

PROSPERO International prospective register of systematic reviews

PROSPERO International prospective register of systematic reviews PROSPERO International prospective register of systematic reviews Drug-eluting balloon angioplasty versus non-stenting balloon angioplasty for peripheral arterial disease of the lower limbs [Cochrane Protocol]

More information

[No conflicts of interest]

[No conflicts of interest] [No conflicts of interest] Patients and staff at: Available evidence pre-calories Three meta-analyses: Gramlich L et al. Does enteral nutrition compared to parenteral nutrition result in better outcomes

More information

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 Mitchell M. Levy MD, MCCM Professor of Medicine Chief, Division of Pulmonary, Sleep, and Critical Care

More information

Agomelatine versus placebo: A meta-analysis of published and unpublished trials

Agomelatine versus placebo: A meta-analysis of published and unpublished trials Agomelatine versus placebo: A meta-analysis of published and unpublished trials (Protocol for a systematic review, Ulm, January 17, 2011) Markus Kösters, Andrea Cipriani, Giuseppe Guaiana, Thomas Becker

More information

A COMMON REFERENCE-BASED INDIRECT COMPARISON META-ANALYSIS OF ESLICARBAZEPINE VERSUS LACOSAMIDE AS ADD ON TREATMENTS FOR FOCAL EPILEPSY PROTOCOL

A COMMON REFERENCE-BASED INDIRECT COMPARISON META-ANALYSIS OF ESLICARBAZEPINE VERSUS LACOSAMIDE AS ADD ON TREATMENTS FOR FOCAL EPILEPSY PROTOCOL A COMMON REFERENCE-BASED INDIRECT COMPARISON META-ANALYSIS OF ESLICARBAZEPINE VERSUS LACOSAMIDE AS ADD ON TREATMENTS FOR FOCAL EPILEPSY PROTOCOL Francesco Brigo 1,2 1 Department of Neurological and Movement

More information

Antifibrinolytic drugs for acute traumatic injury(review)

Antifibrinolytic drugs for acute traumatic injury(review) Cochrane Database of Systematic Reviews Antifibrinolytic drugs for acute traumatic injury(review) KerK,RobertsI,ShakurH,CoatsTJ KerK,RobertsI,ShakurH,CoatsTJ. Antifibrinolytic drugs for acute traumatic

More information

Source of effectiveness data The effectiveness data were derived from a review and synthesis of completed studies.

Source of effectiveness data The effectiveness data were derived from a review and synthesis of completed studies. Economic evaluation of maintenance therapies for reflux esophagitis: comparison between step-up therapies and step-down therapies Sugano K, Kobayashi M Record Status This is a critical abstract of an economic

More information

surgery: A systematic review and meta-analysis protocol

surgery: A systematic review and meta-analysis protocol Title Perioperative dexmedetomidine and outcomes after adult cardiac surgery: A systematic review and meta-analysis protocol Registration PROSPERO (registered December 8 th, 2015) Authors David McIlroy

More information

Simon Everett. Consultant Gastroenterologist, SJUH, Leeds. if this is what greets you in the morning, you probably need to go see a doctor

Simon Everett. Consultant Gastroenterologist, SJUH, Leeds. if this is what greets you in the morning, you probably need to go see a doctor Simon Everett Consultant Gastroenterologist, SJUH, Leeds if this is what greets you in the morning, you probably need to go see a doctor Presentation Audit data and mortality NICE guidance Risk assessment

More information

TITLE: Fusidic Acid for Ophthalmic Infections: A Review of Clinical and Cost Effectiveness and Safety

TITLE: Fusidic Acid for Ophthalmic Infections: A Review of Clinical and Cost Effectiveness and Safety TITLE: Fusidic Acid for Ophthalmic Infections: A Review of Clinical and Cost Effectiveness and Safety DATE: 22 February 2013 CONTEXT AND POLICY ISSUES The antibiotic fusidic acid is available in a 1% suspension

More information

SUMMARY INTRODUCTION. Accepted for publication 11 May 2005

SUMMARY INTRODUCTION. Accepted for publication 11 May 2005 Aliment Pharmacol Ther 2005; 22: 169 174. doi: 10.1111/j.1365-2036.2005.02546.x Systematic review and meta-analysis: proton-pump inhibitor treatment for ulcer bleeding reduces transfusion requirements

More information

Quick Literature Searches

Quick Literature Searches Quick Literature Searches National Pediatric Nighttime Curriculum Written by Leticia Shanley, MD, FAAP Institution: University of Texas Southwestern Medical Center Case 1 It s 1:00am and you have just

More information

Systematic review with multiple treatment comparison metaanalysis. on interventions for hepatic encephalopathy

Systematic review with multiple treatment comparison metaanalysis. on interventions for hepatic encephalopathy Systematic review with multiple treatment comparison metaanalysis on interventions for hepatic encephalopathy Hepatic encephalopathy (HE) is a reversible neuropsychiatric syndrome associated with severe

More information

STRATEGIES TO IMPROVE ENTERAL FEEDING TOLERANCE. IS IT WORTH IT? ENGELA FRANCIS RD(SA)

STRATEGIES TO IMPROVE ENTERAL FEEDING TOLERANCE. IS IT WORTH IT? ENGELA FRANCIS RD(SA) STRATEGIES TO IMPROVE ENTERAL FEEDING TOLERANCE. IS IT WORTH IT? ENGELA FRANCIS RD(SA) DEFINITION OF ENTERAL FEEDING INTOLERANCE Gastrointestinal feeding intolerance are usually defined as: High gastric

More information

Meta-analyses: analyses:

Meta-analyses: analyses: Meta-analyses: analyses: how do they help, and when can they not? Lee Hooper Senior Lecturer in research synthesis & nutrition l.hooper@uea.ac.uk 01603 591268 Aims Systematic Reviews Discuss the scientific

More information

Positioning Biologics in Ulcerative Colitis

Positioning Biologics in Ulcerative Colitis Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies

More information

UPDATE IN HOSPITAL MEDICINE

UPDATE IN HOSPITAL MEDICINE UPDATE IN HOSPITAL MEDICINE FLORIDA CHAPTER ACP MEETING 2016 Himangi Kaushal, M.D., F.A.C.P. Program Director Memorial Healthcare System Internal Medicine Residency DISCLOSURES None OBJECTIVES Review some

More information

Recommendations for Hospital Quality Measures in 2011:

Recommendations for Hospital Quality Measures in 2011: Pediatric Measures: Recommendations for Hospital Quality Measures in 2011: Based on the input of a group of healthcare stakeholders, the following new hospital measures are recommended: 1) Home Management

More information